Myovant Sciences Ltd.
CIK 0001679082
Revenue (TTM)
$33.33M
Q3 Jan 2023
Net Income (TTM)
−$187.93M
+19.3% YoY
Q3 Jan 2023
EPS Diluted (TTM)
−$1.96
+21.6% YoY
Q3 Jan 2023
Gross Margin
—
Q3 Jan 2023
Operating Margin
-464.1%
Q3 Jan 2023
Net Margin
-563.8%
Q3 Jan 2023
Free Cash Flow (TTM)
−$318.34M
Q3 Jan 2023
Cash
$250.59M
Q3 Jan 2023
Total Debt
$0
Q3 Jan 2023
Shares Outstanding
97.24M sh
Q3 Jan 2023
Revenue & Net Income
EPS (Diluted)
Cash Flow
Revenue Growth (YoY)
No data available for this metric.